← Back to Nuqta Atlas
Editorially curated · ae-abu-dhabi-precision-oncology
Abu Dhabi Personalised Precision Medicine Programme for Oncology
Clinical pathway using hereditary cancer genomics and precision medicine to tailor surveillance, treatment, and family cascade testing.
01 / Project overview
What the record establishes.
- Geographic scope
- Abu Dhabi emirate
- Project type
- clinical precision-oncology program
- Research domain
- cancer genomics, hereditary cancer, and cascade screening
- Years
- 2022–
- Lifecycle status
- active
- Status basis
- DoH reported in December 2024 that the program had supported 256 Emirati cancer patients and screened relatives.
- Status evidence date
- 2024-12-01
- Scale
- 256 Emirati cancer patients; 47-gene hereditary cancer screen; 207 relatives reported assessed by December 2024.
02 / Organizations and population
Who and what the project connects.
- Lead organizations
- Department of Health - Abu Dhabi
- Partner organizations
- Mubadala Health · Cleveland Clinic Abu Dhabi · New York University Abu Dhabi · Mohamed bin Zayed University of Artificial Intelligence · G42 Healthcare
- Organism / population
- Emirati cancer patients and relatives; initial focus on breast cancer
03 / Data and access
What exists and how it can be reached.
Data types
- cancer gene panel
- germline variants
- clinical phenotypes
- cascade testing
Data access
Clinical access only; aggregate reporting is public.
Identifiers
No public accession or identifier is listed for this record.
04 / Evidence and provenance
Why the record is included.
Inclusion basis
Named multi-patient cancer-genomics implementation with quantitative outcomes and family cascade testing.
Editorial note
Initial breast-cancer focus has broader hereditary-cancer relevance; no open tumor/genome dataset identified.
Sources
- primary record source Verified 2026-08-15
- additional record source Verified 2026-08-15
Release v0.2.0